Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00320398
Other study ID # AR3106333
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 30, 2006
Est. completion date July 18, 2006

Study information

Verified date August 2018
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).


Recruitment information / eligibility

Status Completed
Enrollment 114
Est. completion date July 18, 2006
Est. primary completion date July 18, 2006
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR.

Exclusion Criteria:

- Active, clinically significant bleeding (excluding drainage).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fondaparinux


Locations

Country Name City State
GSK Investigational Site

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With Venous Thromboembolism (VTE) During Efficacy Period The percentage of participants with VTE, who underwent elective total hip replacement surgery, detected by routine venography, during the treatment period were reported. The percentage VTE was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the Central Independent Adjudication Committee of Efficacy (CIACE). Up to Day 17
Primary Percentage of Participants With Major Bleeding Major bleeding defined as any clinically unusual bleeding meeting 1 of following criteria; a)Fatal bleeding; b) Including retroperitoneal and intracranial bleeding, or bleeding into critical organ (eye, adrenal gland, pericardium, spine); c) Reoperation due to bleeding or hematoma at operative site; d)Bleeding leading to hemoglobin (Hb) fall > = 2 gram per deciliter (g/dL)(1.6 millimole per litre [mmol/L]) within 48 hour of the bleed; e)Bleeding that required transfusion of red blood cells (RBCs) or whole blood (WB) derived from >= 900 milliliter (mL) of WB within 48 hours of the bleed (excluding autologous transfusion except for treatment of bleeding adverse event); f) Bleeding leading to bleeding index (BI) >=2. The percentage was calculated by the number of events divided by the number of participants evaluated multiplied by 100. This was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With Minor Bleeding Minor bleeding was defined as the clinically overt bleeding not meeting the criteria for major bleeding like: (Fatal bleed; Including retroperitoneal and intracranial bleeding, or bleed in critical organ [eye, adrenal gland, pericardium, spine]; c) Reoperation due to bleeding or hematoma at operative site; d) Bleeding leading to hemoglobin (Hb) fall > = 2 g/dL(1.6 mmol/L) within 48 hour of the bleed; e)Bleeding that required transfusion of RBCs or WB derived from >= 900 mL of WB within 48 hours of the bleed (excluding autologous transfusion except for treatment of bleeding adverse event); f) Bleeding leading to bleeding index (BI) >=2), and which were considered more than expected in the clinical context. The percentage was calculated by the number of events divided by the number of participants evaluated multiplied by 100. This was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With All Deep Vein Thrombosis (DVT) The percentage of participants with All DVT were reported, where the analysis was done using a venogram. It was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With Proximal DVT The percentage of participants with DVT (proximal) were reported, by using a venogram. It was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With Distal Only DVT The percentage of participants with distal only DVT were reported, by using a venogram. It was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With Symptomatic DVT During Main Efficacy Period The percentage of participants with different symptoms of DVT (proximal) like pain or tenderness, swelling, warmth, redness or discoloration, and distention of surface veins, post the total hip replacement surgery were reported, where analysis was done using a venogram. It was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the CIACE. Up to Day 17
Secondary Percentage of Participants With Pulmonary Embolism During Efficacy Period The percentage of participants with pulmonary embolism (pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia ) were reported, by using a venogram. It was calculated by the number of events divided by the number of participants evaluated multiplied by 100. The Venogram was obtained post 2 calendar days after the administration of last study drug (between Day 11 and 17). Day 1 was the day of surgery and the participant was given study drug 24±2 hours after surgical closure. It was adjudicated by the CIACE. Up to Day 17
Secondary Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. From first injection of study drug (Day 3) to up to 2 calendar days after last injection (Treatment period), up to Day 17.
Secondary Number of Transfused Participants The number of participants who received RBCs or WB after the total hip replacement surgery within 48 hours of bleed were reported. Up to Day 17.
Secondary Volume of Transfusion The total volume of transfusion (RBCs or WB) received by the participant was reported. Up to Day 17
See also
  Status Clinical Trial Phase
Completed NCT04503135 - Catheter Associated Asymptomatic Thrombosis in Intensive Care Unit
Completed NCT01691495 - ARIXTRA® Adherence in SVT Patients. N/A
Not yet recruiting NCT06149533 - Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients Phase 3
Active, not recruiting NCT05396157 - Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Completed NCT00312013 - Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer Phase 3
Not yet recruiting NCT06288906 - Acute and Subacute Iliofemoral and/or Caval Deep Vein Thrombosis: Evaluation of Mechanical Thrombectomy Systems
Completed NCT00443053 - Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) Phase 3
Completed NCT00911157 - The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients Phase 3
Completed NCT01064362 - Hemorrhage Risk Prescribed Arixtra N/A
Recruiting NCT06440044 - Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism
Completed NCT01444612 - Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery N/A
Recruiting NCT05710705 - Bioimpedance Measurement of Abdominal Free Flaps During Arterial and Venous Weaning in Breast Reconstruction N/A
Completed NCT00843492 - A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery Phase 3
Not yet recruiting NCT06349291 - Venous Thrombosis After Removal of Central Venous Catheter
Recruiting NCT06094387 - The Use of Thrombin Generation Assay in Detection of Central Line Related Thrombosis (CRT) in Critically Ill Patients